AbbVie: Rinvoq And Skyrizi Will Bridge US Humira Sales Erosion Through 2025
Executive Summary
Continuing its longstanding effort to assure investors about growth past Humira’s US patent expiry in 2023, the pharma outlined label-expansion and market share plans for its two newer immunology drugs.
You may also be interested in...
AbbVie Stays On Script With Michael As Next CEO
As previously indicated, AbbVie will go with an internal candidate, president and COO Robert Michael, to succeed Richard Gonzalez as CEO. The company has recently positioned Michael prominently.
AbbVie: Expect Smaller Deals Near-Term After 2023’s Big Finish
At the J.P. Morgan conference, AbbVie president Robert Michael said the company must effectively integrate ImmunoGen and Cerevel, which it expects to drive long-term growth.
AbbVie’s Immunology Growth Strategy Is Delivering, But Imbruvica Reduced By IRA
AbbVie’s $2.1bn write down of Imbruvica’s value is tied directly to Medicare drug price negotiations. Humira’s US biosimilar erosion continued as projected, while the Skyrizi/Rinvoq duo are set to top Humira peak sales by 2027.